WO2005039588A3 - Methods for determining the risk of developing liver and lung toxicity - Google Patents

Methods for determining the risk of developing liver and lung toxicity Download PDF

Info

Publication number
WO2005039588A3
WO2005039588A3 PCT/EP2004/011921 EP2004011921W WO2005039588A3 WO 2005039588 A3 WO2005039588 A3 WO 2005039588A3 EP 2004011921 W EP2004011921 W EP 2004011921W WO 2005039588 A3 WO2005039588 A3 WO 2005039588A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
lung toxicity
determining
risk
individual
Prior art date
Application number
PCT/EP2004/011921
Other languages
French (fr)
Other versions
WO2005039588A2 (en
Inventor
Kenneth Wayne Culver
David Parkinson
Diane Mccarthy
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
David Parkinson
Diane Mccarthy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, David Parkinson, Diane Mccarthy filed Critical Novartis Ag
Publication of WO2005039588A2 publication Critical patent/WO2005039588A2/en
Publication of WO2005039588A3 publication Critical patent/WO2005039588A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Methods are disclosed for, predicting the probability or likelihood that an individual will develop hepatotoxicity or lung toxicity when treated with a therapeutic or study agent that has the potential to cause liver or lung toxicity and methods for detecting at an early stage the development of hepatoxicity during treatment with a potentially hepatotoxic therapeutic or study agent. These methods involve determining the level of serum amyloid A or the gene expression products of the SERPINA3 gene, either mRNA or protein, in the body fluids or tissues of the individual. Kits for the performance of these assays are also provided. A method is disclosed using [11(R)-4-[(1-phenylethyl)amino]-7H-pyrrolo [2,3-d] pyrimidin -6-yl] -phenol in the manufacture of a medicament for the treatment of proliferative disease.
PCT/EP2004/011921 2003-10-22 2004-10-21 Methods for determining the risk of developing liver and lung toxicity WO2005039588A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51324503P 2003-10-22 2003-10-22
US60/513,245 2003-10-22

Publications (2)

Publication Number Publication Date
WO2005039588A2 WO2005039588A2 (en) 2005-05-06
WO2005039588A3 true WO2005039588A3 (en) 2005-10-06

Family

ID=34520084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011921 WO2005039588A2 (en) 2003-10-22 2004-10-21 Methods for determining the risk of developing liver and lung toxicity

Country Status (1)

Country Link
WO (1) WO2005039588A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005592A1 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
US7883858B2 (en) * 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
ES2573954T3 (en) 2008-12-30 2016-06-13 Children's Medical Center Corporation Acute appendicitis prediction method
US9458232B2 (en) * 2013-07-16 2016-10-04 The Feinstein Institute For Medical Research SAA domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
CN109187994A (en) * 2018-09-14 2019-01-11 苏州普瑞斯生物科技有限公司 A kind of kit and preparation method of the concentration measuring serum amyloid A protein

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002266A1 (en) * 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5773220A (en) * 1995-07-28 1998-06-30 University Of Pittsburgh Determination of Alzheimer's disease risk using apolipoprotein E and .alpha.
WO2001032155A2 (en) * 1999-11-02 2001-05-10 The University Of Manchester Use of egfr tyrosine kinase inhibitors for treating breast cancer
WO2003012450A1 (en) * 2001-08-02 2003-02-13 The Scripps Research Institute Diagnostic markers of liver dysfunction
US20030065000A1 (en) * 2001-09-07 2003-04-03 Cohen Pamela Sarah Method of treating cancer
WO2003030908A2 (en) * 2001-10-09 2003-04-17 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
WO2003037897A2 (en) * 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
WO2003065993A2 (en) * 2002-02-04 2003-08-14 Gene Logic, Inc. Primary rat hepatocyte toxicity modeling

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002266A1 (en) * 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5773220A (en) * 1995-07-28 1998-06-30 University Of Pittsburgh Determination of Alzheimer's disease risk using apolipoprotein E and .alpha.
WO2001032155A2 (en) * 1999-11-02 2001-05-10 The University Of Manchester Use of egfr tyrosine kinase inhibitors for treating breast cancer
WO2003012450A1 (en) * 2001-08-02 2003-02-13 The Scripps Research Institute Diagnostic markers of liver dysfunction
US20030065000A1 (en) * 2001-09-07 2003-04-03 Cohen Pamela Sarah Method of treating cancer
WO2003030908A2 (en) * 2001-10-09 2003-04-17 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
WO2003037897A2 (en) * 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
WO2003065993A2 (en) * 2002-02-04 2003-08-14 Gene Logic, Inc. Primary rat hepatocyte toxicity modeling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAKER C H ET AL: "BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING ON TUMOR CELLS AND TUMOR-ASSOCIATED ENDOTHELIAL CELLS FOR THERAPY OF HUMAN CARCINOMAS", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 161, no. 3, September 2002 (2002-09-01), pages 929 - 938, XP008014432, ISSN: 0002-9440 *
BRUNS C J ET AL: "BLOCKADE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING BY A NOVEL TYROSINE KINASE INHIBITOR LEADS TO APOPTOSIS OF ENDOTHELIAL CELLS AND THERAPY OF HUMAN PANCREATIC CARCINOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 11, 1 June 2000 (2000-06-01), pages 2926 - 2935, XP001009785, ISSN: 0008-5472 *
HOLSINGER F CHRISTOPHER ET AL: "Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 AUG 2003, vol. 9, no. 8, 1 August 2003 (2003-08-01), pages 3183 - 3189, XP008046602, ISSN: 1078-0432 *
MELLINGHOFF INGO K ET AL: "Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.", CANCER RESEARCH. 15 SEP 2002, vol. 62, no. 18, 15 September 2002 (2002-09-15), pages 5254 - 5259, XP008046598, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2005039588A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
HK1181816A1 (en) Markers for detection of gastric cancer
WO2005055810A3 (en) Risk markers for cardiovascular disease
EP1870466A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2005062770A3 (en) Method for conducting pharmacogenomics-based studies
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2005039588A3 (en) Methods for determining the risk of developing liver and lung toxicity
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2004071273A3 (en) Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005011619A3 (en) Lung-expressed polypeptides
WO2004083449A3 (en) Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase